Cargando…

Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells

Oxaliplatin‐based systemic chemotherapy has been proposed to have efficacy in hepatocellular carcinoma (HCC). We investigated the combination of vorinostat and oxaliplatin for possible synergism in HCC cells. SMMC7721, BEL7402, and HepG2 cells were treated with vorinostat and oxaliplatin. Cytotoxici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Bo, Zhang, Yingying, Sun, Quan, Jiang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773972/ https://www.ncbi.nlm.nih.gov/pubmed/29239146 http://dx.doi.org/10.1002/cam4.1278

Ejemplares similares

Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin
por: Wang, Xiumei, et al.
Publicado: (2020)

FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma
por: Zhong, Cheng‐Qian, et al.
Publicado: (2018)

Evaluation of anticancer effects of Juniperus communis extract on hepatocellular carcinoma cells in vitro and in vivo
por: Huang, Nan-Chieh, et al.
Publicado: (2021)

Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
por: Pan, Chun-Hao, et al.
Publicado: (2016)

Overactivated neddylation pathway in human hepatocellular carcinoma
por: Yu, Jian, et al.
Publicado: (2018)

Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line
por: Li, Nainong, et al.
Publicado: (2015)

Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization
por: Greenlee, Joshua D, et al.
Publicado: (2021)

Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15
por: Dong, Gang, et al.
Publicado: (2018)

Circular RNAs in hepatocellular carcinoma: Functions and implications
por: Fu, Liyun, et al.
Publicado: (2018)

Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma
por: Han, Ke‐qi, et al.
Publicado: (2016)

MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial‐mesenchymal transition of glioblastoma cells in vitro and in vivo
por: Liu, Tie, et al.
Publicado: (2019)

Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma
por: Hu, Bo, et al.
Publicado: (2020)

Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway
por: Sun, Ruijie, et al.
Publicado: (2019)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

MiR‐101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma
por: Xu, Fei, et al.
Publicado: (2017)

Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells
por: Zhong, Xiaowei, et al.
Publicado: (2020)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma
por: Jiang, Hai, et al.
Publicado: (2018)

Oxaliplatin regulates myeloid‐derived suppressor cell‐mediated immunosuppression via downregulation of nuclear factor‐κB signaling
por: Kim, Na‐Rae, et al.
Publicado: (2018)

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles
por: Meka, Anand Kumar, et al.
Publicado: (2018)

NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma
por: Wang, Xiangkun, et al.
Publicado: (2017)

Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride production
por: Zhang, Shuai, et al.
Publicado: (2021)

Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma
por: Xia, Yujia, et al.
Publicado: (2021)

The role of mesenchymal stem cells in the occurrence, development, and therapy of hepatocellular carcinoma
por: Zhang, Xiaoli, et al.
Publicado: (2022)

Metformin revert insulin‐induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells
por: Liu, Chao, et al.
Publicado: (2020)

Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
por: Wu, Fangming, et al.
Publicado: (2020)

Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma
por: Jiang, Zhenluo, et al.
Publicado: (2019)

TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma
por: Zhou, Shuang, et al.
Publicado: (2019)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

Sp2 promotes invasion and metastasis of hepatocellular carcinoma by targeting TRIB3 protein
por: Zhu, Yue, et al.
Publicado: (2020)

PTTG1 is involved in TNF‐α‐related hepatocellular carcinoma via the induction of c‐myc
por: Lin, Xianyi, et al.
Publicado: (2019)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Systematic analyses of a novel lncRNA‐associated signature as the prognostic biomarker for Hepatocellular Carcinoma
por: Sui, Jing, et al.
Publicado: (2018)

A signature of 33 immune‐related gene pairs predicts clinical outcome in hepatocellular carcinoma
por: Sun, Xiao‐Yan, et al.
Publicado: (2020)

Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma
por: Zheng, Ruipeng, et al.
Publicado: (2020)

Does timing matter in radiotherapy of hepatocellular carcinoma? An experimental study in mice
por: Hassan, Soha A., et al.
Publicado: (2021)

CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5‐FU‐induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway
por: Sun, Yi, et al.
Publicado: (2017)

Overexpression of SRC‐3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness
por: Xu, Fang‐Ping, et al.
Publicado: (2016)

Circ‐SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR‐33a to promote hepatocellular carcinoma tumorigenesis
por: Zhang, Bin, et al.
Publicado: (2020)

miR‐206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9
por: Pang, Chi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5e7vi3q8res43gn0n0p57ak01q